Oral Pharmacology in Type II Diabetes

The management of Type II Diabetes Mellitus (T2DM) has evolved significantly with the advent of diverse oral pharmacologic therapies. This 1.25-hour CME/CE course provides a foundational overview of the pharmacological agents used in the treatment of type 2 diabetes mellitus (T2DM). It emphasizes glycemic targets, prescribing guidelines, and a clear understanding of the mechanisms of action and potential side effects of these medications.

Participants will be introduced to the classification and diagnostic criteria for type 2 diabetes mellitus (T2DM), followed by an exploration of individualized glycemic goals in alignment with national clinical guidelines. The course explores various classes of oral antidiabetic agents, including biguanides, sulfonylureas, DPP-4 inhibitors, SGLT2 inhibitors, and thiazolidinediones, with a focus on their efficacy, safety, indications, and contraindications. This course prepares providers to implement a team-based and patient-centered approach that optimizes therapeutic outcomes while minimizing risks.

This activity fulfills state-mandated pharmacology education requirements for physicians, physician assistants, and nurses across multiple states, including Massachusetts, Ohio, Rhode Island, Maryland, Alabama, Indiana, and the District of Columbia.

Educational Objectives

• Recognize the classification and diagnostic criteria used in evaluating Type II Diabetes Mellitus.
• Identify appropriate glycemic goals and clinical guidelines for the management of type 2 diabetes mellitus (T2DM).
• Understand the mechanisms of action, clinical indications, side effects, and contraindications of oral pharmacologic agents used to treat T2DM.

Who Should Take This Course

This course is ideal for:

• Physicians, Physician Assistants, and Nurses in states such as Massachusetts, Ohio, Rhode Island, Maryland, Alabama, Indiana, and the District of Columbia.
• Providers working in primary care, endocrinology, internal medicine, or chronic disease management.
• Healthcare professionals seeking to fulfill continuing education requirements in Pharmacology.
• Clinicians who want a practical and up-to-date review of oral medications used in Type II Diabetes Mellitus treatment.

Did You Know?

• Type II Diabetes affects over 37 million people in the U.S., with more than 90% using oral medications as part of their treatment. [CDC, 2022]
• Metformin, a biguanide, remains the first-line treatment due to its efficacy, low cost, and safety profile. [ADA Guidelines, 2023]
• SGLT2 inhibitors not only lower blood glucose but also reduce cardiovascular and renal risk in T2DM patients. [NEJM, 2019]
• Polypharmacy in T2DM is a common challenge, requiring careful medication review to avoid adverse interactions. [Journal of Diabetes Research, 2020]
• Personalized glycemic targets are essential, especially in elderly patients or those with comorbid conditions. [AACE Guidelines, 2023]